Teva ($TEVA) has already surprised analysts with the success it's had converting patients from multiple sclerosis star Copaxone to a new, long-acting version. And now, the company is preparing to take the med to Europe. On Thursday, Teva announced it had received a positive outcome in the decentralized procedure for the drug and that "granting of national authorizations will happen in the near future." The Israeli drugmaker plans to make the med available on the continent as early as the first quarter of 2015, with launches in Germany, Netherlands and Denmark, it said. It expects others to follow throughout the year. Release | More